Grant Wickman

1.9k total citations · 1 hit paper
21 papers, 1.4k citations indexed

About

Grant Wickman is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Grant Wickman has authored 21 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Grant Wickman's work include Monoclonal and Polyclonal Antibodies Research (6 papers), HER2/EGFR in Cancer Research (4 papers) and Cell death mechanisms and regulation (3 papers). Grant Wickman is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), HER2/EGFR in Cancer Research (4 papers) and Cell death mechanisms and regulation (3 papers). Grant Wickman collaborates with scholars based in Canada, United Kingdom and United States. Grant Wickman's co-authors include Michael F. Olson, Linda Julian, Dana D. Hu‐Lowe, Jeffrey H. Chen, Karin Amundson, Robert S. Kania, Maren L. Grazzini, David R. Shalinsky, Michele McTigue and Helen Y. Zou and has published in prestigious journals such as The Journal of Cell Biology, Blood and Circulation Research.

In The Last Decade

Grant Wickman

19 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

2008 515 citations Dana D. Hu‐Lowe, Helen Y. Zou et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Grant Wickman Canada	13	764	374	291	279	188	21	1.4k
Mark N. Adams Australia	21	908 1.2×	385 1.0×	204 0.7×	307 1.1×	170 0.9×	65	1.5k
Alastair H. Kyle Canada	21	730 1.0×	465 1.2×	207 0.7×	410 1.5×	125 0.7×	49	1.5k
Qian Zhan United States	21	948 1.2×	729 1.9×	155 0.5×	262 0.9×	260 1.4×	36	1.6k
Andrei Turtoï France	27	1.1k 1.4×	580 1.6×	246 0.8×	483 1.7×	312 1.7×	64	1.9k
Motoyoshi Tanaka Japan	22	919 1.2×	361 1.0×	244 0.8×	258 0.9×	159 0.8×	49	1.5k
Punit Saraon Canada	19	805 1.1×	236 0.6×	240 0.8×	267 1.0×	152 0.8×	25	1.5k
Victor Stastny United States	15	917 1.2×	443 1.2×	141 0.5×	324 1.2×	119 0.6×	24	1.4k
Mark Esposito United States	13	786 1.0×	466 1.2×	172 0.6×	364 1.3×	138 0.7×	19	1.3k
Cameron N. Johnstone Australia	24	1.1k 1.4×	555 1.5×	165 0.6×	445 1.6×	324 1.7×	38	1.7k
Hanna Romańska United Kingdom	21	756 1.0×	302 0.8×	397 1.4×	274 1.0×	113 0.6×	58	1.7k

Countries citing papers authored by Grant Wickman

Since Specialization

Citations

This map shows the geographic impact of Grant Wickman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grant Wickman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grant Wickman more than expected).

Fields of papers citing papers by Grant Wickman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Grant Wickman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grant Wickman. The network helps show where Grant Wickman may publish in the future.

Co-authorship network of co-authors of Grant Wickman

This figure shows the co-authorship network connecting the top 25 collaborators of Grant Wickman. A scholar is included among the top collaborators of Grant Wickman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grant Wickman. Grant Wickman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wickman, Grant, et al.. (2025). The Combination of APG777 (anti-IL-13) and APG333 (anti-TSLP) Inhibits Central and Local Drivers of Obstructive Airway Disease. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A2489–A2489. 1 indexed citations

Zhu, Eric, et al.. (2025). In vitro potency and pharmacokinetics of APG777, a novel anti–IL-13 mAb. Journal of Allergy and Clinical Immunology Global. 4(4). 100545–100545.

Julian, Linda, Grant Wickman, Nicola Rath, et al.. (2021). Defective apoptotic cell contractility provokes sterile inflammation, leading to liver damage and tumour suppression. eLife. 10. 10 indexed citations

Sanches, Mário, I. D’Angelo, María Jaramillo, et al.. (2020). AlbuCORE: an albumin-based molecular scaffold for multivalent biologics design. mAbs. 12(1). 1802188–1802188. 3 indexed citations

Hamblett, Kevin J., R. H. Davies, Grant Wickman, et al.. (2018). Abstract 3914: ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers. Cancer Research. 78(13_Supplement). 3914–3914. 37 indexed citations

Weisser, Nina E., et al.. (2017). Abstract 31: Preclinical development of a novel biparatopic HER2 antibody with activity in low to high HER2 expressing cancers. Cancer Research. 77(13_Supplement). 31–31. 31 indexed citations

Ng, Gordon, Thomas Spreter, R. H. Davies, & Grant Wickman. (2016). ZW38, a Novel Azymetric Bispecific CD19-Directed CD3 T Cell Engager Antibody Drug Conjugate with Controlled T Cell Activation and Improved B Cell Cytotoxicity. Blood. 128(22). 1841–1841. 5 indexed citations

Wickman, Grant, Linda Julian, Katerina Mardilovich, et al.. (2013). Blebs produced by actin–myosin contraction during apoptosis release damage-associated molecular pattern proteins before secondary necrosis occurs. Cell Death and Differentiation. 20(10). 1293–1305. 155 indexed citations

Wickman, Grant, Linda Julian, & Michael F. Olson. (2012). How apoptotic cells aid in the removal of their own cold dead bodies. Cell Death and Differentiation. 19(5). 735–742. 189 indexed citations

10.

Li, Gang, Lianglin Zhang, Enhong Chen, et al.. (2010). Dual Functional Monoclonal Antibody PF-04605412 Targets Integrin α5β1 and Elicits Potent Antibody-Dependent Cellular Cytotoxicity. Cancer Research. 70(24). 10243–10254. 20 indexed citations

11.

Lochhead, Pamela A., Grant Wickman, Mokdad Mezna, & Michael F. Olson. (2010). Activating ROCK1 somatic mutations in human cancer. Oncogene. 29(17). 2591–2598. 73 indexed citations

12.

Morin, Pierre, Grant Wickman, June Munro, Gareth J. Inman, & Michael F. Olson. (2010). Differing contributions of LIMK and ROCK to TGFβ-induced transcription, motility and invasion. European Journal of Cell Biology. 90(1). 13–25. 31 indexed citations

13.

Hooper, Steven, Diane Crighton, Ang Li, et al.. (2010). LIM kinases are required for invasive path generation by tumor and tumor-associated stromal cells. The Journal of Cell Biology. 191(1). 169–185. 143 indexed citations

14.

Hu‐Lowe, Dana D., Helen Y. Zou, Maren L. Grazzini, et al.. (2008). Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3. Clinical Cancer Research. 14(22). 7272–7283. 515 indexed citations breakdown →

15.

Hu‐Lowe, Dana D., Maren L. Grazzini, Karin Amundson, et al.. (2006). 71 POSTER Antiangiogenic inhibitor axitinib (AG-013736) renders significant growth inhibition of bevacizumab-refractory xenograft tumors. European Journal of Cancer Supplements. 4(12). 25–25. 1 indexed citations

16.

Zou, Helen Y., Qiuhua Li, Maren L. Grazzini, et al.. (2004). AG-028262, a novel selective VEGFR tyrosine kinase antagonist that potently inhibits KDR signaling and angiogenesis in vitro and in vivo. Cancer Research. 64. 595–595. 7 indexed citations

17.

Wickman, Grant, et al.. (2003). Functional Roles of the Rho/Rho Kinase Pathway and Protein Kinase C in the Regulation of Cerebrovascular Constriction Mediated by Hemoglobin. Circulation Research. 92(7). 809–816. 80 indexed citations

18.

Wickman, Grant, et al.. (2001). The polycationic aminoglycosides modulate the vasoconstrictive effects of endothelin: relevance to cerebral vasospasm. British Journal of Pharmacology. 133(1). 5–12. 12 indexed citations

19.

Wickman, Grant & Bozena Vollrath. (2000). Effects of tamoxifen on oxyhemoglobin-induced cerebral vasoconstriction. European Journal of Pharmacology. 390(1-2). 181–184. 7 indexed citations

20.

Rı́os, José Luis, et al.. (1990). A study on the anti-inflammatory activity of Cayaponia tayuya root.. Fitoterapia. 61(3). 275–278. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact